Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia

References

• Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085
   PubMed Web of Science ®Google Scholar
• Feller N, van der Pol M A, van Stijn A, Weijers G W, Westra A H, Evertse B W, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380–1390
   PubMed Web of Science ®Google Scholar
• Baer M R. Detection of minimal residual disease in acute myeloid leukemia. Curr Oncol Rep 2002; 4: 398–402
   PubMedGoogle Scholar
• Campana D, Pui C H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416–1434
   PubMed Web of Science ®Google Scholar
• Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823–838
   PubMed Web of Science ®Google Scholar
• Macedo A, Orfao A, Gonzalez M, Vidriales M B, Lopez-Berges M C, Martinez A, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995; 9: 993–998
   PubMed Web of Science ®Google Scholar
• Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755
   PubMed Web of Science ®Google Scholar
• Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443–449
   PubMed Web of Science ®Google Scholar
• Yin J A, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002; 360: 160–162
   PubMed Web of Science ®Google Scholar
• Schoch C, Kern W, Krawitz P, Dugas M, Schnittger S, Haferlach T, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001; 98: 3500
   PubMed Web of Science ®Google Scholar
• Munoz L, Nomdedeu J F, Villamor N, Guardia R, Colomer D, Ribera J M, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17: 76–82
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004; 112: 68–78
   PubMed Web of Science ®Google Scholar
• Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000; 14: 796–804
   PubMed Web of Science ®Google Scholar
• Stirewalt D L, Willman C L, Radich J P. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res 2001; 25: 1085–1088
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Ribeiro R C, Rubnitz J E, Razzouk B I, Pui C H, Pounds S, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243–252
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Vidriales M B, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746–1751
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948–3952
   PubMed Web of Science ®Google Scholar
• Sievers E L, Lange B J, Alonzo T A, Gerbing R B, Bernstein I D, Smith F O, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003; 101: 3398–3406
   PubMed Web of Science ®Google Scholar
• Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb H J, et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow. Haematologica 2003; 88: 646–653
   PubMed Web of Science ®Google Scholar
• Kern W, Schnittger S. Monitoring of AML by flow cyometry. Curr Oncol Rep 2003; 5: 405–412
   PubMedGoogle Scholar
• Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 2004; 89: 528–540
   PubMed Web of Science ®Google Scholar
• Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004; 112: 8–15
   PubMed Web of Science ®Google Scholar
• Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T, Kern W. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004; 62B: 25–38
   Web of Science ®Google Scholar
• Kern W, Voskova D, Schnittger S, Schoch C, Hiddemann W, Haferlach T. Fourfold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. Hematol J 2004; 5: 410–418
   PubMedGoogle Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Buchner T, Willman C L, Estey E H, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Haferlach T, Schoch C, Loffler H, Gassmann W, Kern W, Schnittger S, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003; 21: 256–265
   PubMed Web of Science ®Google Scholar
• Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120–125
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362–1370
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Berdel W E, Wormann B, Schoch C, Fonatsch C, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the german AML cooperative group. J Clin Oncol 2003; 21: 4496–4504
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64–70
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of highdose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116–4124
   PubMed Web of Science ®Google Scholar
• Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig W D, Fischer J, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583–1589
   PubMed Web of Science ®Google Scholar
• Kern W, Kohlmann A, Wuchter C, Schnittger S, Schoch C, Mergenthaler S, et al. Correlation of protein expression and gene expression in acute leukemia. Cytometry 2003; 55B: 29–36
   Google Scholar
• Borowitz M J, Guenther K L, Shults K E, Stelzer G T. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993; 100: 534–540
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457–481
   Web of Science ®Google Scholar